n |
31 |
11 |
12 |
|
Age (years) |
57.00 [51.50, 68.50] |
60.00 [55.50, 68.00] |
55.00 [50.25, 61.50] |
0.466 |
Gender (% male) |
20 (64.5) |
2 (18.2) |
4 (33.3) |
0.016 |
BMI |
23.00 [22.00, 27.00] |
27.00 [23.00, 34.50] |
25.00
[22.00, 28.00] |
0.207 |
CRSwNP (%) |
6 (19.4) |
4 (36.4) |
7 (58.3) |
0.050 |
FEV1 (predicted %) |
67.00 [54.75, 81.75] |
72.50 [59.75,
82.25] |
77.00 [65.50, 86.50] |
0.589 |
Total IgE measurment (kU/l) |
289.00 [112.50, 1115.00] |
78.00
[16.50, 127.00] |
184.50 [66.00, 500.00] |
0.014 |
Eosinophil cells blood count ( G/L) |
0.25 [0.13, 0.65] |
0.22
[0.06, 0.58] |
0.16 [0.05, 0.74] |
0.811 |
Oral cortisteroid at baseline (%) |
6 (19.4) |
6 (60.0) |
7 (63.6) |
0.008 |
Oral corticosteroid dose at baseline |
0.00 [0.00, 0.00] |
8.75
[0.00, 13.75] |
10.00 [0.00, 20.00] |
0.010 |
Rate of severe exacerbation the year before evaluation |
1.00 [0.50,
4.00] |
4.00 [1.50, 8.00] |
4.00 [2.50, 6.00] |
0.061 |
Omalizumab efficacy (%) |
20 (64.5) |
6 (54.5) |
6 (50.0) |
0.694 |